Coulter Partners successfully completed a search assignment for NeoPhore Limited and is pleased to announce the placement of Michael Shih as Chief Executive Officer (CEO) and Board of Director.

NeoPhore, a small molecule neoantigen immuno-oncology company, is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the DNA mismatch repair (MMR) pathway to improve the efficacy and durability of revolutionary immunotherapies to treat cancer.

Michael Shih is a highly experienced business development executive with nearly 20 years of success in driving strategic growth. He has a proven track record in leading and executing successful business development transactions, including licensing, mergers & acquisitions, and strategic collaborations.

Robert James, Chairman of the Board, NeoPhore, said: “Michael joins at an exciting stage in NeoPhore’s development having raised a significant Series B financing round which was supported by Bristol Myers Squibb. As we move closer to being a clinical Company, Michael’s experience as a corporate development leader in pharma and biotech will be instrumental in driving NeoPhore’s next phase of growth.”

Michael Shih, newly appointed Chief Executive Officer and Board of Director, NeoPhore commented: “NeoPhore’s differentiated approach to targeting the MMR pathway has huge potential to treat cancer. I am looking forward to working with the highly experienced NeoPhore team, who are all clearly aligned to advance the Company’s pipeline.”

----

Michael Shih, Chief Executive Officer of NeoPhore

Michael Shih has nearly 20 years of experience in business development, licensing and mergers & acquisitions. He was most recently Vice President of Corporate Development at Kite Pharma, where he led multiple business development opportunities for the Company. Before this, Michael was Senior Vice President, Head of Business Development at Biogen, leading the team responsible for sourcing, structuring and executing strategic collaborations and merger and acquisition opportunities. Prior to joining Biogen, Michael was Vice President and Head of Global Transactions at Sanofi, where he oversaw the structuring and negotiation of business development transactions across Sanofi’s business units. Michael has also held senior business development roles at Epizyme, Forest Laboratories and Eisai.

About NeoPhore

NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumors can be exploited by the patients’ immune system to overcome natural defense mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund.

For more information, please visit www.neophore.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners secures CEO Placement for NeoPhore

About NeoPhore

About Coulter Partners

Related

Bio€quity Europe 2025

#Twenty25 - Funding the future of health tech - Part 19/20 Interview with Inga Deakin, Molten Ventures

#Twenty25 - Funding the future of health tech - Part 18/20 Interview with Issy Gordon, Salica Investments

#Twenty25 - Funding the future of health tech - Part 17/20 Interview with Molly Gilmartin, AlbionVC